SiteBridge Research and iParticipate Launch Annual Bridging the Gap in Clinical Trials Arts Contest
SiteBridge Research, together with iParticipate, is kicking off its annual Bridging the Gap in Clinical Trials Arts contest. This effort officially launches SiteBridge's community engagement program and aims to connect the arts, sciences, and community in support of clinical trial participation.
The contest began on June 14 with voting commencing on August 7. Winners will be notified on November 20. It will feature talent across four categories: visual art, music, photography, and dance.
SiteBridge's creative collaboration with iParticipate, incorporated in the "Bridging the Gap" initiative compels industry to examine how it addresses disparities and how it portrays clinical trials—especially to communities of color and other underrepresented populations—and will explore the potential for impact.
Read more about the initiative and contest here.
Reference
Bridging the Gap Community Engagement Program. (2023, June 14). SiteBridge Research.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
